Renal Cell Carcinoma Clinical Trials

A listing of Renal Cell Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 257 clinical trials
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.

nephrectomy
carcinoma
clear cell renal cell carcinoma
pet scan
  • 21 views
  • 12 May, 2021
  • 40 locations
Renal Adjuvant MultiPle Arm Randomised Trial

RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients

metastasis
neutrophil count
systemic therapy
ct scan
nephrectomy
  • 60 views
  • 25 Jan, 2021
  • 35 locations
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood …

arrhythmia
metastasis
interleukin-2
platelet count
carcinoma
  • 17 views
  • 07 Nov, 2020
  • 2 locations
A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.

  • 47 views
  • 22 Jan, 2021
  • 5 locations
Phase I Tolerability Efficacy and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

Combination of anti-angiogenic molecular targeted therapy and anti- programmed cell death -1 immune checkpoint inhibitor (ICI) therapy has shown promising antitumor activity in multiple cancer types, including patients with advanced hepatocellular carcinoma (HCC). The safety profile and optimal dosage of targeted therapy should be carefully evaluated by clinical trials. Regorafenib …

  • 0 views
  • 28 Jan, 2021
  • 1 location
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Phase II Study of Tegafur/Uracil (UFUR )Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Primary objective: To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma. Secondary objectives: 1. To determine the disease stabilization rate; 2. To assess the progression-free survival and overall survival; 3. To establish the safety profile; 4. To evaluate the …

radiofrequency ablation
neutrophil count
ct scan
arterial embolization
local therapy
  • 4 views
  • 07 Nov, 2020
  • 1 location
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in …

  • 7 views
  • 16 Jul, 2021
  • 8 locations
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

This is an open label, prospective, trial that begins with a phase Ib safety run-in followed by a phase II expansion cohort.

metastasis
bone metastases
neutrophil count
prostate adenocarcinoma
nivolumab
  • 0 views
  • 26 Jan, 2021
  • 1 location